严重喘中的生物学因素:从精确的表型化到临床缓解
1Lianyungang Municipal Oriental Hospital, The Affiliated Lianyungang Municipal Oriental Hospital of Kangda College of Nanjing Medical University, No. 57, Zhonghua West Road, Lianyun District, Lianyungang City, Jiangsu Province, China, 222042.
概括
生物疗法显著减少严重喘恶化和口服皮质类固醇的使用. 生物标志物引导的治疗选择有助于实现临床缓解,改善患者的治疗结果和生活质量.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重喘管理正在向个性化医学发展.
- 生物疗法在治疗严重喘方面取得了重大进展.
- 了解生物标志物驱动的策略是优化治疗的关键.
研究的目的:
- 批判性地评估当前严重喘的生物疗法.
- 综合生物标志物引导治疗选择的证据.
- 评估严重喘管理中临床缓解的目标.
主要方法:
- 在主要数据库 (PubMed,Embase,Cochrane) 的系统文献搜索.
- 包括随机对照试验,现实世界的证据,系统审查和元分析.
- 专注于批准和新兴的生物药物治疗严重喘.
主要成果:
- 生物药物显著降低了恶化 (26-56%与安慰剂相比) 和口服皮质类固醇依赖.
- 生物标志物 (血液中的乙氨基基,FeNO,IgE) 指导治疗选择.
- 临床缓解 (无症状,无恶化,OCS独立) 在32-50%的患者中是可以实现的.
- 佩鲁马布在更广泛的人群中显示出有效性,包括那些患有下T2炎症的人.
结论:
- 严重喘管理已经转向精准医学方法.
- 生物药物使许多患者能够获得临床缓解.
- 未来的研究应该涉及非T2喘,动态生物标志物和长期影响.
相关概念视频
Asthma: Pathogenesis and Management
1.6K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.2K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.2K
Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Asthma-II: Pathophysiology and Classification
4.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.8K
Antiasthma Drugs: Leukotriene Modifiers
2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.1K
Drugs Used in Lower Respiratory Disorders: Overview
1.4K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.4K


